Manning & Napier Advisors LLC Sells 115,040 Shares of Johnson & Johnson $JNJ

Manning & Napier Advisors LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 43.8% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 147,340 shares of the company’s stock after selling 115,040 shares during the period. Manning & Napier Advisors LLC’s holdings in Johnson & Johnson were worth $27,320,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson during the 2nd quarter worth approximately $27,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson during the third quarter worth $28,000. Semmax Financial Advisors Inc. lifted its stake in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the last quarter. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $35,000. Finally, Signature Resources Capital Management LLC grew its position in Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after acquiring an additional 184 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ stock opened at $218.81 on Friday. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $220.11. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a 50 day simple moving average of $205.82 and a two-hundred day simple moving average of $186.74. The company has a market cap of $527.18 billion, a P/E ratio of 21.12, a PEG ratio of 2.26 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 14th. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.76 by $0.04. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $23.99 billion during the quarter, compared to the consensus estimate of $23.73 billion. During the same quarter last year, the firm posted $2.42 EPS. The company’s quarterly revenue was up 6.8% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Analyst Ratings Changes

A number of brokerages have recently commented on JNJ. The Goldman Sachs Group lifted their price target on Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Raymond James Financial raised their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Finally, Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $213.33.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.